• 主题
高级搜索  >
历史搜索 清空历史
首页> 外文期刊>Expert opinion on pharmacotherapy >Single inhaler triple therapy with extrafine beclomethasone, formoterol, and glycopyrronium for the treatment of chronic obstructive pulmonary disease
【24h】

Single inhaler triple therapy with extrafine beclomethasone, formoterol, and glycopyrronium for the treatment of chronic obstructive pulmonary disease

机译：单次吸入器三重疗法与外列甲基塞洛塞，福莫特罗和糖酮用于治疗慢性阻塞性肺病

获取原文
获取原文并翻译 | 示例
       
页面导航
  • 摘要
  • 著录项
  • 相似文献
  • 相关主题

摘要

Introduction: Chronic obstructive pulmonary disease (COPD) management focuses on the alleviation of symptoms and prevention of exacerbations. Inhaled long acting bronchodilators and inhaled corticosteroids (ICS) are the main classes of treatment for COPD. Triple therapy with a long acting beta2-agonist (LABA), long acting muscarinic antagonist (LAMA), and ICS is commonly prescribed for symptomatic COPD patients experiencing regular exacerbations. Triple therapy is usually administered using separate inhalers; there is little clinical trial evidence of an effect on exacerbation prevention with this approach. Areas covered: This evaluation reviews the single inhaler extrafine combination containing beclometasone diproprionate (BDP), formoterol fumarate (FF), and glycopyrronium bromide (GB) which has been developed as a simplified triple regime. BDP/FF/GB significantly reduced exacerbation rates in three clinical trials (1-year duration) compared against LAMA monotherapy (20% exacerbation reduction), ICS/LABA combination (23% exacerbation reduction), and LAMA/LABA combination (15% exacerbation reduction). Expert opinion: The practical benefits of single inhaler triple therapy in the real world have not been studied. However, the robust clinical trial evidence that BDP/FF/GB reduces exacerbations compared to double combination treatments and LAMA monotherapy cements triple therapy positioning as an escalation step in COPD management pathways.
机译：介绍：慢性阻塞性肺病（COPD）管理侧重于减轻症状和加剧的预防。吸入长的支气管扩张剂和吸入的皮质类固醇（ICS）是对COPD治疗的主要阶段。三重疗法具有长效的β2-激动剂（Laba），长期肌肉蛋白拮抗剂（喇嘛）和ICS通常为患有常规恶化的症状COPD患者规定。通常使用单独的吸入器施用三重疗法;几乎没有临床试验证据对这种方法加剧预防的临床试验。所涵盖的区域：该评估评估含有伯莫酮二氢丙酸酯（BDP），Formoterol富马酸盐（FF）和糖酮（GB）的单一吸入器外列组合，所述溴化铜溴（GB）已经开发为简化的三重制度。 BDP / FF / GB在三种临床试验中显着降低了加剧率（1年持续时间），与喇嘛单药治疗（20％加剧还原），ICS / Laba组合（减少23％）和喇嘛/拉巴组合（15％恶化）减少）。专家意见：在现实世界中单一吸入器三重治疗的实际益处尚未研究过。然而，与双重组合治疗和喇嘛单药治疗水泥三重治疗定位作为COPD管理途径的升级步骤，BDP / FF / GB减少了加剧的临床试验证据。

著录项

相似文献

  • 外文文献
  • 中文文献
  • 专利
获取原文

客服邮箱：kefu@zhangqiaokeyan.com

京公网安备：11010802029741号 ICP备案号：京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有

  • 客服微信

  • 服务号